Statins Show Primary Prevention Benefit in Older Adults

A major randomized trial, known as the STAREE (Statin Therapy for Older Adults to Reduce Events) trial, has provided the first clear evidence that statin therapy offers a primary prevention benefit for healthy older adults. The study, which involved participants aged 70 years and older, found that daily treatment with atorvastatin 40 mg was significantly favored over a placebo in reducing major cardiovascular events. This finding addresses a long-standing question in clinical practice regarding the utility of statins for preventing heart disease and stroke in individuals who have not previously experienced such events but are in an older age group.

The STAREE trial enrolled 18,000 participants and was conducted over a median follow-up period of 5.2 years. The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or sustained ventricular tachycardia/ventricular fibrillation. According to the results published in The New England Journal of Medicine, the incidence of the primary composite endpoint was 5.0% in the atorvastatin group compared to 6.1% in the placebo group. This represented a 16% relative risk reduction, with a hazard ratio of 0.84 (95% CI, 0.73 to 0.96; P=0.01).

Beyond the primary endpoint, the trial also reported on secondary outcomes. There was a statistically significant reduction in the incidence of stroke in the atorvastatin group (2.2% vs. 2.9%, hazard ratio 0.76; 95% CI, 0.63 to 0.93; P=0.007). However, there was no significant difference in cardiovascular death (2.5% vs. 2.7%, hazard ratio 0.93; 95% CI, 0.78 to 1.11; P=0.42) or nonfatal myocardial infarction (1.1% vs. 1.3%, hazard ratio 0.87; 95% CI, 0.68 to 1.11; P=0.27) between the two groups. The incidence of all-cause mortality was also similar, with 8.5% in the atorvastatin group and 8.9% in the placebo group (hazard ratio 0.95; 95% CI, 0.85 to 1.06; P=0.36).

Safety data from the STAREE trial indicated that adverse events were generally well-tolerated. Muscle-related symptoms, a common concern with statin use, were reported at similar rates in both groups. The trial was conducted across multiple centers in Australia and New Zealand, with funding from the National Health and Medical Research Council of Australia and the National Heart Foundation of Australia. The findings of the STAREE trial are expected to influence clinical guidelines for the use of statins in primary prevention for older adults, potentially expanding the population eligible for this treatment to reduce cardiovascular risk.